Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer

Front Cell Dev Biol. 2016 Sep 21;4:103. doi: 10.3389/fcell.2016.00103. eCollection 2016.

Abstract

Colorectal cancer is the third most common cancer worldwide and is associated with significant morbidity and mortality. Current pharmacotherapy options include cytotoxic chemotherapy, anti-VEGF, and anti-EGFR targeting drugs, but these are limited by toxic side effects, limited responses and ultimately resistance. Cysteinyl leukotriene (CysLT) signaling regulates intestinal homeostasis with mounting evidence suggesting that CysLT signaling also plays a role in the pathogenesis of colorectal cancer. Therefore, CysLT signaling represents a novel target for this malignancy. This review evaluates reported links between CysLT signaling and established hallmarks of cancer in addition to its pharmacological potential as a new therapeutic target.

Keywords: colorectal cancer; cysteinyl leukotriene; cysteinyl leukotriene receptor antagonist; eicosanoid; hallmarks of cancer; tumorigenesis.

Publication types

  • Review